U.S. Viscosupplementation Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

The U.S. Viscosupplementation Market, valued at USD 1.1 billion in 2023, is projected to grow at a CAGR of 7.6%. Viscosupplementation, a minimally invasive treatment for osteoarthritis symptoms like pain and stiffness, is gaining traction due to the rising prevalence of osteoarthritis, especially in aging people. As people age, increased joint wear and tear leads to a higher incidence of osteoarthritis.

The market growth is further driven by a preference for non-surgical treatments and a rising demand for pain management solutions. Viscosupplements are seen as a viable alternative to surgery, offering relief without the risks associated with invasive procedures. Technological advancements, such as improved formulations and delivery methods, have also expanded the market's potential.

Viscosupplementation predominantly treats osteoarthritis, especially in the knee joint, by injecting hyaluronic acid into the joint for lubrication and cushioning. Hyaluronic acid, naturally found in synovial fluid, acts as a lubricant and shock absorber. In osteoarthritis, synovial fluid becomes thinner and less effective, increasing joint friction and pain. Injecting hyaluronic acid aims to restore the fluid's viscosity and elasticity, reducing pain and improving joint function.

The U.S. viscosupplementation market segments products into single injections, 3 injections, and 5 injections. In 2023, the 3 injections segment led the market with a 45.6% share and is expected to grow at a 7.7% CAGR during the analysis period. This regimen is supported by robust clinical evidence demonstrating its effectiveness in relieving osteoarthritis symptoms and improving joint function. Its optimal treatment duration, flexible dosage, convenient schedule, and widespread clinical acceptance contribute to its anticipated growth.

Based on the source of origin, the market is divided into avian and non-avian origins. The non-avian segment held a significant market share in 2023 and is projected to reach USD 1.6 billion by 2032. This growth is attributed to reduced allergic reaction risks, ethical and environmental considerations, and consistency and purity assurances. The increasing demand for non-animal-derived products further boosts the segment's popularity. Advances in biotechnology and fermentation processes for non-avian products are expected to drive market growth.

Segmented by end-use, the market includes hospitals, ambulatory surgical centers, and other users. In 2023, hospitals dominated the market share and are forecasted to grow at a 7.5% CAGR from 2024 to 2032. Hospitals offer comprehensive healthcare services, including specialized treatments like viscosupplementation for osteoarthritis, attracting a significant patient base. The rising incidence of osteoarthritis in the U.S., the proliferation of hospitals and clinics, and the availability of advanced medical technologies further bolster this segment's leading market share.